Literature DB >> 16107633

Response of a nonmalignant pleural effusion to bevacizumab.

Oskar Pichelmayer, Christoph Zielinski, Markus Raderer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16107633     DOI： 10.1056/NEJM200508183530722

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

2.  Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.

Authors:  Katsuhiro Masago; Daichi Fujimoto; Shiro Fujita; Akito Hata; Reiko Kaji; Kyoko Ohtsuka; Chiyuki Okuda; Jumpei Takeshita; Nobuyuki Katakami
Journal:  Mol Clin Oncol       Date:  2014-11-19

3.  Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.

Authors:  Hui Zhao; Xiaosong Li; Dianjun Chen; Jianhua Cai; Yan Fu; Huanrong Kang; Jie Gao; Ke Gao; Nan Du
Journal:  Med Oncol       Date:  2015-01-22       Impact factor: 3.064

4.  Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report.

Authors:  Toshikazu Araoka; Hiroya Takeoka; Keisuke Nishioka; Masaki Ikeda; Makiko Kondo; Azusa Hoshina; Seiji Kishi; Makoto Araki; Rokuro Mimura; Taichi Murakami; Akira Mima; Kojiro Nagai; Hideharu Abe; Toshio Doi
Journal:  J Med Case Rep       Date:  2010-10-18

Review 5.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

6.  Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema.

Authors:  Masaki Watanabe; Julie L Boyer; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2009-06       Impact factor: 5.695

7.  A case of cardiac amyloidosis with diuretic-refractory pleural effusions treated with bevacizumab.

Authors:  Suk-Hyang Bae; Jin Yeon Hwang; Woo Jae Kim; Hyun-Hwa Yoon; Jung Min Kim; Young Hee Nam; Hee Gyung Baek; Yong Rak Cho; Sun-Yi Park; Jeong Hwan Kim; Sung-Hyun Kim; Tae-Ho Park; Gi-Nam Lee; Seo-Hee Rha; Young Dae Kim
Journal:  Korean Circ J       Date:  2010-12-31       Impact factor: 3.243
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.